Recent activities

From the lab · Publication and news [New Publication] Primed human pluripotent stem cell-derived blastocyst-like cell aggregates with partial lineage specification Published 2025-11-12 Our latest paper, “Primed human pluripotent stem cell-derived blastocyst-like cell aggregates with partial lineage specification,” has been published in Regenerative Therapy (Elsevier, 2025) — DOI: 10.1016/j.reth.2025.10.007. We Read more…

Our latest research has been published in Chemical Engineering Journal: Title: Nanoengineered Redox-Responsive Platforms for Dual-Targeted NSCLC Therapy with Tumor-on-a-Chip Epithelial-Mesenchymal Transition Profiling In this work, we present a rationally designed binary hybrid nanoassembly (OL@R NPs) that co-delivers a redox-responsive platinum(IV) prodrug of oxaliplatin and the ferroptosis inducer RSL3. This Read more…

We are thrilled to share our latest research in collaboration with Shenyang Pharmaceutical University! Our study, led by Dr. Chutong Tian, introduces a self-motivated carrier-free nanoplatform that synergizes photodynamic therapy (PDT) and ferroptosis for targeted anticancer treatment. Title: A self-motivated carrier free nanoplatform for synergistic photodynamic and ferroptosis-based therapy for Read more…

Exciting News! Our latest work in Carbon presents a stimulus-responsive, carrier-free prodrug nano-delivery system for enhanced cancer therapy. By designing ROS-responsive SN38-CA@FC nanoparticles, we achieve a synergistic effect of chemotherapy and ferroptosis, leveraging tumor-specific smart drug release. This approach not only enhances SN38’s therapeutic efficacy but also disrupts redox homeostasis, Read more…